StocksRunner logo
 
  Overview  
 
  Chart  
 
  Earnings  
 
  Sentiment  
 
  Highlights  
 
  Updates  
 
 
 
BioNTech
90.94
+2.23%
 

BNTX

 

BioNTech

$ 90.94

 
+$1.98 | +2.23%
 
 
Open
$ 89.70
 
 
MKT CAP
$ 21.62B
 
High
$ 92.31
 
 
VOL
$ 674.30K
 
Low
$ 89.46
 
 
AVG VOL
$ 0.62M
 
 
 

BNTX Stock Analysis

  Login to display BioNTech (BNTX) recommendation from the last 90 days from financial news and social media.
 
 

BNTX Total Score

 
 

Strengths

BNTX Rewards

 Earnings are forecast to grow

 
 

Chart

 
 

98.22

99.4

93.24

128.88

 
 
1month
3month
6month
1year
 

BNTX Risk Level

This Indicator assigning BNTX risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.

 
BNTX Risk Level
LOW
HIGH

Risk Volatility

 

BNTX has Low Risk Level

Click here to check what is your level of risk

 

BNTX Analysts Opinion

BNTX overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information

 
 

Earnings

×
 

Earnings

2.00
 

BNTX Earnings Sentiment

 Below analyst estimate

 
 

Rating

×
 

Rating

1.75
 
 

Momentum

×
 

Momentum

3.00
 
 

Activity

×
 

Activity

2.73
 
 

Future

×
 

Future

3.33
 

BNTX Future Sentiment

 Earnings are forecast to grow

 
 

BNTX Analysts Opinion

BNTX Analysts opinion is negative and it remained unchanged from the past 3 months

 

BNTX Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

 
44%
Buy
Opinion
Trend
Score
Potential
Score
 
 
0%
50%
75%
 
On Track
On Track
On Track
 

BNTX Street Opinion 

BNTX Street view is unimpressive but have positive views on the near-term outlook

 

BNTX Performance Sentiment

Sentiments overview associated with BNTX events and the stock performance.
 
44%
56%
Positive
Negative
24 out of 54
events present
30 out of 54
events present
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 

BNTX Earnings

The TTM reflects 12-month period, providing review of BNTX financial performance.

 
Millions of Dollars
TTM
2022
2021
CAGR
 

 
Total Revenue
6,618
17,311
18,977
-40.95%
 
 
Cost of Revenue
2,319
4,532
3,861
-22.50%
 
 
Gross Profit
4,299
12,779
15,116
-46.67%
 
 
Operating Exp
533
478
198
+64.07%
 
 
Operating Inc
3,766
12,301
14,918
-49.76%
 
 
Net Interest Inc
269
30
-26
-
 
 
Interest Exp
4
16
5
-10.56%
 
 
Interest Inc
276
49
2
+1074.73%
 
 
Other Income
-340
624
154
 
 
EPS
11.27
38.78
42.18
-48.31%
 
 
Next Earnings Date: Mar 20, 2024
 
 
Highlights
Last Modify
Price
% Change

 
Concerns
This Week
91.43
-1.47%
 
Concerns
2 Weeks Ago
91.46
+0.97%
 
Concerns
3 Weeks Ago
93.14
-1.02%
 
Concerns
2 Month Ago
94.51
-0.56%
 
Concerns
2 Month Ago
95.78
+1.03%
 
 
 
joker
 
 
 
StocksRunner

Explore our BNTX Stock insights

  • In-Depth Market Analysis and Trends
  • Expert Insights on Market Dynamics
  • Tailored FDX Stock Strategies
  • Effective Risk Management
 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our BNTX Daily Alerts

Access the exclusive insights that over 10,000+ subscribers value. Stay ahead in the stock market! Submit your email for daily alerts.

 
Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

 
Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

 
Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

 
About StocksRunner

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
StocksRunner logo

StocksRunner

Get the pulse of the market

 
StocksRunner
 
 
 
 

Stock Insights

 
 
 
 

Strengths

 

BNTX Rewards

 Earnings are forecast to grow

 
 
 

BNTX Risk Level

 
 
 

The Indicator assigning BNTX risk levels based on factors such as volatility, sector strength, trading volume, investor confidence and market outlook.

 
 
BNTX Risk Level
LOW
HIGH

Risk Volatility

 

BNTX has Low Risk Level. Click here to check what is your level of risk

 
 
 
 

Stock Analysis

 
 
 
 

BNTX

 

BioNTech

$ 90.94

 
+$1.98 | +2.23%
 
  Overview  
 
  Chart  
 
  Earnings  
 
  Sentiment  
 
  News  
 
  Updates  
 

 
joker
 
 
 
Open
$ 89.70
 
 
MKT CAP
$ 21.62B
 
High
$ 92.31
 
 
VOL
$ 674.30K
 
Low
$ 89.46
 
 
AVG VOL
$ 0.62M
 
 
 

BNTX Analysis

  Sign in to view BioNTech (BNTX) recommendation from the last 90 days from financial news and social media.
 
 

Chart

 
 

98.22

99.4

93.24

128.88

 
 
1month
3month
6month
1year
 

BNTX Analysts Opinion

BNTX Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information

 
 

Earnings

×
 

Earnings

2.00
 

BNTX Earnings Sentiment

 Below analyst estimate

 
 

Rating

×
 

Rating

1.75
 
 

Momentum

×
 

Momentum

3.00
 
 

Activity

×
 

Activity

2.73
 
 

Future

×
 

Future

3.33
 

BNTX Future Sentiment

 Earnings are forecast to grow

 
 

BNTX Analysts Opinion

BNTX Analysts opinion is negative and it remained unchanged from the past 3 months

 

BNTX Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

 
44%
Buy
Opinion
Trend
Score
Potential
Score
 
 
0%
50%
75%
 
On Track
On Track
On Track
 

BNTX Street Opinion 

BNTX Street view is unimpressive but have positive views on the near-term outlook

 
BNTX Performance Sentiment
Sentiments overview associated with BNTX events and the stock performance.
 
44%
56%
Positive
Negative
24 out of 54
events present
30 out of 54
events present
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 

BNTX Earnings

The TTM data reflects the most recent 12-month period, providing overview of BNTX financial performance.

 
Millions of Dollars
TTM
2022
2021
CAGR
 

 
Total Revenue
6,618
17,311
18,977
-40.95%
 
 
Cost of Revenue
2,319
4,532
3,861
-22.50%
 
 
Gross Profit
4,299
12,779
15,116
-46.67%
 
 
Operating Exp
533
478
198
+64.07%
 
 
Operating Inc
3,766
12,301
14,918
-49.76%
 
 
Net Interest Inc
269
30
-26
-
 
 
Interest Exp
4
16
5
-10.56%
 
 
Interest Inc
276
49
2
+1074.73%
 
 
Other Income
-340
624
154
 
 
EPS
11.27
38.78
42.18
-48.31%
 
 
Next Earnings Date: Mar 20, 2024
 
Highlights
Last Modify
Price
% Change

 
Concerns
This Week
91.43
-1.47%
 
Concerns
2 Weeks Ago
91.46
+0.97%
 
Concerns
3 Weeks Ago
93.14
-1.02%
 
Concerns
2 Month Ago
94.51
-0.56%
 
Concerns
2 Month Ago
95.78
+1.03%
 
 
BNTX Latest News Feed

BNTX Investors Have Opportunity to Lead BioNTech SE Securities Fraud Lawsuit. LOS ANGELES Feb. 28 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP (GPM) announces that investors with substantial losses have opportunity to lead the securities fraud class a

Wed Feb 28, 2024

Activity
Potential

BioNTech Buys Into Autolus Cell Therapy Tech - Why I Expect A Full Acquisition In Time.

Thu Feb 22, 2024

Activity

Cracking The Code: Understanding Analyst Reviews For BioNTech. During the last three months 4 analysts shared their evaluations of BioNTech (NASDAQ:) revealing diverse outlooks from ish to bearish. The table below offers a condensed view of their recent

Tue Feb 20, 2024

Potential

Kessler Topaz Meltzer &. Check LLP Reminds BNTX Investors of March 12 2024 Deadline in Securities Fraud Class Action against of BioNTech SE (BNTX) and Urges Investors with Substantial Losses to Contact the Firm. RADNOR Pa. Feb. 17 2024 /PRNewswire/ --

Sat Feb 17, 2024

Activity

ROSEN LEADING INVESTOR COUNSEL Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX. NEW YORK Feb. 17 2024 /PRNewswire/ -- WHY: Rosen Law Firm a global investor rights law firm reminds purchasers o

Sat Feb 17, 2024

Activity

BIONTECH SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100000 In BioNTech To Contact Him Directly To Discuss Their Options. If you suffered losses exceeding $100000 inves

Fri Feb 16, 2024

Activity

Shareholders that lost money on BioNTech SE (BNTX) should contact Levi &. Korsinsky about pending Class Action - BNTX. NEW YORK Feb. 16 2024 /PRNewswire/ -- Levi & Korsinsky LLP notifies investors in BioNTech SE (BioNTech or the Company) (NASDAQ: BNTX)

Fri Feb 16, 2024

Activity
Potential

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTech SE of Class Action Lawsuit and Upcoming Deadlines - BNTX. NEW YORK Feb. 15 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has

Thu Feb 15, 2024

Activity
Activity

BNTX Investors Have Opportunity to Lead BioNTech SE Securities Fraud Lawsuit. LOS ANGELES Feb. 14 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP (GPM) announces that investors with substantial losses have opportunity to lead the securities fraud class a

Wed Feb 14, 2024

Activity
Potential

ROSEN A TOP RANKED LAW FIRM Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX. NEW YORK Feb. 10 2024 /PRNewswire/ -- WHY: Rosen Law Firm a global investor rights law firm reminds purchasers of

Sat Feb 10, 2024

Activity
Potential

bntx investors have opportunity to lead biontech se securities fraud lawsuit. bensalem pa. feb. 9 2024 /prnewswire/ -- law offices of howard g. smith announces that investors with substantial losses have opportunity to lead the securities fraud class acti

Fri Feb 9, 2024

Activity
Potential

the gross law firm announces the filing of a securities class action on behalf of biontech se(bntx) shareholders. new york feb. 9 2024 /prnewswire/ -- the gross law firm issues the following notice to shareholders of biontech se. shareholders who purchase

Fri Feb 9, 2024

Activity

rosen a ranked and leading firm encourages biontech se investors to secure counsel before important deadline in securities class action – bntx. new york feb. 08 2024 (globe newswire) -- ) between march 30 2022 and october 13 2023 both dates inclusiv

Thu Feb 8, 2024

Activity

biontech to invest $200m in autolus as part of a car-t deal.

Thu Feb 8, 2024

Activity

biontech and autolus announce strategic car-t cell therapy collaboration to advance pipeline and expand late-stage programs  . biontech and autolus announce strategic car-t cell therapy collaboration to advance pipeline and expand late-stage programs

Thu Feb 8, 2024

Activity

market whales and their recent bets on bntx options. high-rolling investors have positioned themselves bearish on biontech (nasdaq:) and it'.s important for retail traders to take note. \this activity came to our attention today through benzinga'

Fri Feb 2, 2024

Potential
Potential

3 biotech stock sensations to snatch up this week. the future of the biotech industry appears promising fueled by technology-driven advancements increasing merger and acquisition maneuvers and developing product pipelines. given this backdrop quality biot

Thu Feb 1, 2024

Activity

shareholder alert: the law offices of vincent wong remind biontech investors of a lead plaintiff deadline of march 12 2024. new york feb. 1 2024 /prnewswire/ -- attention biontech se (biontech) (nasdaq: bntx) shareholders: the law offices of vincent wong

Thu Feb 1, 2024

Activity
Activity

bntx investor alert: bronstein gewirtz & grossman llc announces that biontech se investors with substantial losses have opportunity to lead class action lawsuit!. new york jan. 29 2024 (globe newswire) -- attorney advertising -- bronstein gewirtz &

Mon Jan 29, 2024

Activity
Activity
Potential

shareholder alert: levi & korsinsky notifies biontech se (bntx) investors of a class action lawsuit and upcoming deadline. new york jan. 25 2024 (globe newswire) -- levi &. korsinsky llp notifies investors in ) of a class action securities lawsuit.

Thu Jan 25, 2024

Activity
Activity

biontech challenges astrazeneca with breast cancer precision drug trial. biontech and its partner duality biologics said on monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer taking on a

Mon Jan 22, 2024

Activity

wuxi biontech sign deal for monoclonal antibody discovery.

Thu Jan 11, 2024

Activity

wuxi biologics announces research service agreement with biontech on discovering investigational monoclonal antibodies for developing next-generation therapeutic product candidates.

Wed Jan 10, 2024

Activity

biontech prepares to be commercial ready by 2025 revenue growth expected to return in 2025. on tuesday) outlined priorities at the annual j.p. morgan healthcare conference and said it expects to grow its

Tue Jan 9, 2024

Potential

biontech sets 2024 outlook below consensus.

Tue Jan 9, 2024

Earnings

biontech issues 2024 revenue guidance - quick facts. (rttnews) - biontech se (bntx) said it projects total company revenues of approximately 3 billion euros for financial year 2024 mainly driven by the covid-19 vaccine franchise which is expecte

Tue Jan 9, 2024

Activity

biontech predicts return to revenue growth in 2025.

Tue Jan 9, 2024

Potential

 
 
 
 
 

Score Tracker

 
 
 
Based on 54 events in the last 90 days from financial news and social media. Last updated Mar 1, 2024 23:12 Wall St. time
 
 

BNTX Total Score

 
 
 
 
 
 
 
StocksRunner

Discover BNTX Stock analysis and effective trading strategies with StocksRunner. Gain valuable insights into stock performance, market trends, and the future potential of BNTX. We're here to help you make informed investment decisions today.

 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our BNTX Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

 
Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

BNTX Stock trends

BNTX Stock performance

BNTX Stock analysis

BNTX investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner ideas

Financial Reports

 
 

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
 
Post ×
 
0/666
joker